Buy CytoDyn (CYDY) stock [Updated daily] | finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CytoDyn stock | $2.82

Own CytoDyn stock in just a few minutes.

CytoDyn Inc (CYDY) is a leading biotechnology business based in the US. It opened the day at USD$2.22 after a previous close of USD$2.13. During the day the price has varied from a low of USD$2.22 to a high of USD$2.9. The latest price was USD$2.82 (25 minute delay). CytoDyn is listed on the OTCQB and employs 19 staff. All prices are listed in US Dollars.

How to buy shares in CytoDyn

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CytoDyn. Find the stock by name or ticker symbol: CYDY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CytoDyn reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.82, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CytoDyn, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CytoDyn. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted CytoDyn's share price?

Since the stock market crash in March caused by coronavirus, CytoDyn's share price has had significant positive movement.

Its last close price was USD$2.82, which is 61.17% up on its pre-crash value of USD$1.095 and 256.96% up on the lowest point reached during the March crash when the shares fell as low as USD$0.79.

If you had bought USD$1,000 worth of CytoDyn shares at the start of February 2020, those shares would have been worth USD$642.58 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,861.40.

CytoDyn share price

Use our graph to track the performance of CYDY stocks over time.

CytoDyn shares at a glance

Information last updated 2021-03-30.
OpenUSD$2.22
HighUSD$2.9
LowUSD$2.22
CloseUSD$2.82
Previous closeUSD$2.13
Change USD$0.69
Change % 32.3944%
Volume 9,698,076
Information last updated 2021-03-24.
52-week rangeUSD$0.911 - USD$10.01
50-day moving average USD$4.2794
200-day moving average USD$3.8318
Wall St. target priceUSD$4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.188

Buy CytoDyn shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CytoDyn stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CytoDyn price performance over time

Historical closes compared with the close of $2.82 from 2021-02-25

1 week (2021-04-09) -9.90%
1 month (2021-03-17) 21.03%
3 months (2021-01-15) -45.77%
6 months (2020-10-16) 0.36%
1 year (2020-04-17) 25.33%
2 years (2019-04-17) 526.67%
3 years (2018-04-17) 437.65%
5 years (2016-04-15) 138.98%

CytoDyn financials

Gross profit TTM USD$0
Return on assets TTM -77.37%
Return on equity TTM 0%
Profit margin 0%
Book value $0.005
Market capitalisation USD$1.4 billion

TTM: trailing 12 months

CytoDyn share dividends

We're not expecting CytoDyn to pay a dividend over the next 12 months.

CytoDyn share price volatility

Over the last 12 months, CytoDyn's shares have ranged in value from as little as $0.911 up to $10.01. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.4957. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.

CytoDyn overview

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site